Baekje Shenzhou is a benchmark enterprise for innovative biopharmaceuticals in China. On October 20 19, 165438+ 10, Baekje Shenzhou independently developed Zanubrutinib, a BTK inhibitor, which was approved by the US Food and Drug Administration (FDA) to treat adult patients with mantle cell lymphoma (MCL) who had received at least one treatment in the past. If there is no accident, Zanubrutinib of Baekje Shenzhou will be the second BTK inhibitor in China and the third BTK inhibitor in the world.
In all fairness, there is a huge gap between China's pharmaceutical industry as a whole and Europe and the United States, especially in scientific research. For a long time, a top American pharmaceutical factory has invested more in R&D every year than all the enterprises in China combined! There are many domestic pharmaceutical factories, but few can do research and development and produce high-quality new drugs.
There are nearly 4,000 pharmaceutical companies in China, and less than 100 have innovative drug research and development capabilities. Among the 100 people, it is rare to have the research and development ability of biopharmaceuticals. So why did Baekje Shenzhou give our biopharmaceuticals a shot in the arm?